BOTHELL, Wash.--(BUSINESS WIRE)--April 25, 2006--Seattle Genetics, Inc. (Nasdaq: SGEN - News) today reported results for its first quarter ended March 31, 2006. Revenues for the first quarter of 2006 were $2.1 million, compared to $2.6 million in the first quarter of 2005. Revenues are generated from fees and milestones earned through the company’s antibody-drug conjugate (ADC) technology collaborations.
